首頁 > 市場調查報告書 > 製藥

遲發性藥物市場規模、佔有率、成長分析（按療法、按給藥途徑、按最終用戶、按分銷管道、按地區）—2025 年至 2032 年行業預測

市場調查報告書

商品編碼

1734417

遲發性藥物市場規模、佔有率、成長分析（按療法、按給藥途徑、按最終用戶、按分銷管道、按地區）—2025 年至 2032 年行業預測

Tardive Dyskinesia Treatment Market Size, Share, and Growth Analysis, By Treatment, By Drugs, By Route of administration, By End User, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日期: 2025年05月17日 | 出版商:

SkyQuest | 英文 191 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2023 年全球遲發性藥物市場規模為 36 億美元，預計將從 2024 年的 38.8 億美元成長到 2032 年的 70.8 億美元，預測期內（2025-2032 年）的複合年成長率為 7.8%。

由於精神疾病盛行率的上升和 VMAT2 抑制劑治療的進步，市場格局正在發生重大變化。加強對加速核准的監管支持正在為治療方法的採用創造有利的環境。人們對遲發性的認知不斷提高，鼓勵人們積極治療這種疾病，特別是在醫療保健基礎設施不斷擴大的地區。製藥公司正在積極尋求策略夥伴關係，以加強其研發能力。然而，市場發展面臨治療成本高、現有治療方法的副作用以及新興地區的認知度低等挑戰。此外，患者數量有限意味著研發投入有限，這可能會阻礙未來遲發性治療的廣泛應用。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 公司分部佔有率分析
- 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

Neurocrine Biosciences, Inc.（US）
Teva Pharmaceutical Industries Ltd.（Israel）
H. Lundbeck A/S（Denmark）
AbbVie Inc.（US）
Otsuka Holdings Co., Ltd.（Japan）
Astellas Pharma Inc.（Japan）
Bausch Health Companies Inc.（Canada）
Sumitomo Pharma America, Inc（US）
Reviva Pharmaceuticals Holdings, Inc.（US）
Acadia Pharmaceuticals Inc.（US）
VANDA PHARMACEUTICALS（US）
Eisai Co., Ltd.（Japan）
Zydus Group（India）
Lilly（US）
F. Hoffmann-La Roche Ltd（Switzerland）
Pfizer Inc.（US）
Bristol-Myers Squibb Company（US）
Mallinckrodt（US）

結論和建議

簡介目錄

Product Code: SQMIG35I2373

Global Tardive Dyskinesia Treatment Market size was valued at USD 3.6 billion in 2023 and is poised to grow from USD 3.88 billion in 2024 to USD 7.08 billion by 2032, growing at a CAGR of 7.8% during the forecast period (2025-2032).

Market insights indicate a significant shift in the tardive dyskinesia treatment landscape, driven by the rising prevalence of psychiatric disorders and advancements in VMAT2 inhibitor therapies. The heightened regulatory support for accelerated approvals is fostering a favorable environment for treatment adoption. Increased awareness of tardive dyskinesia, particularly in regions with expanding healthcare infrastructure, is encouraging proactive management of this condition. Pharmaceutical companies are actively pursuing strategic partnerships to enhance research and development efforts. However, the market faces challenges, including high treatment costs, adverse effects associated with current therapies, and limited awareness in developing areas. Additionally, constrained R&D investments due to a smaller patient population may hinder widespread adoption of tardive dyskinesia treatments in the future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Tardive Dyskinesia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Tardive Dyskinesia Treatment Market Segments Analysis

Global Tardive Dyskinesia Treatment Market is segmented by Treatment, Drugs, Route of administration, End User, Distribution Channel and region. Based on Treatment, the market is segmented into Medication and Surgery. Based on Drugs, the market is segmented into Antipsychotics, VMAT2 Inhibitors, Botulinum Toxin, Natural Remedies, Dopamine-Depleting Medications and Others. Based on Route of administration, the market is segmented into Oral and Injectable. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Tardive Dyskinesia Treatment Market

The global tardive dyskinesia (TD) treatment market is significantly driven by the supportive actions of regulatory bodies like the U.S. Food and Drug Administration (FDA), which have implemented expedited approval pathways for TD therapies in acknowledgment of the critical unmet medical needs. These initiatives, including fast-track designations and priority reviews, allow for a swifter market introduction of innovative treatments. This regulatory backing not only encourages pharmaceutical companies to focus their investments on developing medications for TD but also positively influences the overall outlook of the global tardive dyskinesia treatment market, fostering advancements in effective therapeutic options for patients.

Restraints in the Global Tardive Dyskinesia Treatment Market

The Global Tardive Dyskinesia Treatment market faces several constraints that hinder its growth potential. Despite the advancements brought by VMAT2 inhibitors in managing tardive dyskinesia (TD), these treatments are accompanied by adverse effects such as fatigue, depression, and somnolence, which can negatively influence patient adherence and overall quality of life. Consequently, some patients may choose to discontinue their treatment due to these side effects. Furthermore, apprehensions regarding the long-term safety profiles of these medications could lead healthcare providers to be cautious in prescribing them, ultimately slowing the widespread adoption of effective tardive dyskinesia therapies in the market.

Market Trends of the Global Tardive Dyskinesia Treatment Market

The Global Tardive Dyskinesia Treatment market is witnessing a significant trend towards advanced VMAT2 inhibitor therapies, which have transformed the therapeutic landscape for this condition. Medications like valbenazine (Ingrezza) and deutetrabenazine (Austedo) have gained prominence due to their targeted approach in addressing the underlying mechanisms of tardive dyskinesia, resulting in enhanced efficacy and safety profiles compared to traditional treatments. The introduction of innovative formulations, such as Ingrezza Sprinkle, further supports treatment adherence among patients with swallowing difficulties. As research and development in this area continue to grow, advancements in VMAT2 inhibitors are expected to drive market expansion and shape treatment paradigms in the coming years.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies

Global Tardive Dyskinesia Treatment Market Size by Treatment & CAGR (2025-2032)

Market Overview
Medication
Surgery

Global Tardive Dyskinesia Treatment Market Size by Drugs & CAGR (2025-2032)

Market Overview
Antipsychotics
VMAT2 Inhibitors
Botulinum Toxin
Natural Remedies
Dopamine-Depleting Medications
Others

Global Tardive Dyskinesia Treatment Market Size by Route of administration & CAGR (2025-2032)

Market Overview
Oral
Injectable

Global Tardive Dyskinesia Treatment Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals
Homecare
Specialty Clinics
Others

Global Tardive Dyskinesia Treatment Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Others

Global Tardive Dyskinesia Treatment Market Size & CAGR (2025-2032)

North America (Treatment, Drugs, Route of administration, End User, Distribution Channel)
- US
- Canada
Europe (Treatment, Drugs, Route of administration, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment, Drugs, Route of administration, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment, Drugs, Route of administration, End User, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment, Drugs, Route of administration, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Neurocrine Biosciences, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
H. Lundbeck A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Holdings Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sumitomo Pharma America, Inc (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Reviva Pharmaceuticals Holdings, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acadia Pharmaceuticals Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
VANDA PHARMACEUTICALS (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eisai Co., Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Group (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lilly (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mallinckrodt (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments